68Ga-PSMA I&T
PET/CT
PSMA
Primary staging
Prostate cancer
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
18
04
2019
accepted:
04
09
2019
pubmed:
19
9
2019
medline:
15
5
2021
entrez:
19
9
2019
Statut:
ppublish
Résumé
The present study is based on a retrospective analysis of Gallium-68 ( A total of 82 men were included in the study and were imaged with PSMA-positive disease was detected in 83% of patients with 66/82 (80.5%) primary tumours being visualized. PSMA-avid lymph nodes were recorded in 17/82 patients (20.7%, 3 with intermediate-risk and 14 with high-risk PCa); distant disease was found in 14/82 subjects (17.1%, 2 with intermediate-risk and 12 with high-risk PCa). No extraprostatic disease was found in low-risk PCa. SUV In patients with initial diagnosis of intermediate- and high-risk prostate cancer,
Identifiants
pubmed: 31529265
doi: 10.1007/s00259-019-04524-z
pii: 10.1007/s00259-019-04524-z
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-177Références
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):670-677
pubmed: 27896369
J Nucl Med. 2019 Jul;60(7):910-916
pubmed: 30464040
Clin Nucl Med. 2018 Apr;43(4):225-231
pubmed: 29401151
Nucl Med Commun. 2015 Jun;36(6):582-7
pubmed: 25738559
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1455-1462
pubmed: 28474140
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
J Nucl Med. 2018 Mar;59(3):479-485
pubmed: 28887401
Eur Urol. 2015 Feb;67(2):212-9
pubmed: 24882672
J Nucl Med. 2017 Dec;58(12):1962-1968
pubmed: 28522740
Urology. 2010 Jun;75(6):1396-404
pubmed: 19969335
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1629-30
pubmed: 23817686
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
J Urol. 2003 Nov;170(5):1798-803
pubmed: 14532779
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
J Urol. 2004 Jun;171(6 Pt 1):2122-7
pubmed: 15126770
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136
pubmed: 28765998
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):701-709
pubmed: 29280465
World J Urol. 2018 Apr;36(4):519-527
pubmed: 29344682
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Nucl Med Commun. 2017 Nov;38(11):956-963
pubmed: 28922335
J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S
pubmed: 27694178
J Nucl Med. 2019 Jun;60(6):817-823
pubmed: 30389823
Eur Urol. 2016 Mar;69(3):393-6
pubmed: 26116958
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
J Urol. 2014 May;191(5):1280-5
pubmed: 24262495
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20
pubmed: 24072344
J Nucl Med. 2017 Feb;58(2):235-242
pubmed: 27635024
Clin Cancer Res. 2003 Dec 15;9(17):6357-62
pubmed: 14695135
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
J Nucl Med. 2015 Aug;56(8):1169-76
pubmed: 26089548
Appl Radiat Isot. 2013 Jun;76:55-62
pubmed: 23063597
Mol Imaging Biol. 2015 Aug;17(4):575-84
pubmed: 26013479
Ann Nucl Med. 2017 Nov;31(9):696-702
pubmed: 28831739
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945